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Abstract 
A sensitive reversed-phase high-performance liquid chromatographic fluorescence method is described for the 
simultaneous determination f topotecan (I) and the hydrolysed lactone ring-opened product hydroxy acid (II) in plasma nd 
for the determination of I in urine. To 250 /zl of plasma, a 750-/~1 volume of cold methanol was added to stabilize the 
pH-dependent conversion of I into II. In plasma, the lower limit of quantitation (LLQ) for both compounds was 0.10 ng/ml. 
The between-day variation for I at the LLQ was 7.1% and for II was 5.5%. Prior to injection, urine samples were acidified 
with orthophosphoric a id and diluted with phosphate-buffered saline (PBS). In urine, the calibration curve for I was linear 
in the range of 10 to 250 ng/ml and the LLQ was 10 ng/ml. The assay was developed to enable pharmacological analysis of 
I, in on-going phase I and II studies, in patients with solid tumors. 
Keywords : Topotecan 
I. Introduction 
Compound I [(S)-9-dimethylaminomethyl-10-hy- 
droxy-camptothecin, SKF 104864-A] is a semi- 
synthetic water-soluble analogue of camptothecin, 
presently being evaluated in clinical phase I and II 
trials. Compound I is an inhibitor of the nuclear 
enzyme topoisomerase I. It stabilizes the cleavable 
complex between DNA and topoisomerase I, re- 
sulting in single-strand breaks of the DNA and 
finally in cell death. Antitumor activity has been 
demonstrated in pre-clinical models and in phase I
Correspondmg author. 
and II studies [1-6], The results of pre-clinical and 
clinical studies indicate enhanced antineoplastic ac- 
tivity of I when administered aily for prolonged 
periods of time [2,5-9]. 
Compound I is not stable at physiological pH in an 
aqueous olution. It is reversibly hydrolysed from the 
closed-ring lactone (I) to an open-ring form (II) in 
aqueous solution (Fig. 1). Compound II is not 
pharmacologically active [10,11]. 
An HPLC assay for the analysis of I and II in 
human plasma has previously been developed by 
Beijnen et al. [11] with a lower limit of quantitation 
(LLQ), for both compounds, of 1 ng/ml. The present 
methodology was developed because blank plasma 
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Fig. 1. pH-Dependent interconversion f I and II. 
samples revealed an interfering peak at almost the 
same retention time as II. In addition, the plasma 
concentrations in our clinical study, where I is 
administered orally for prolonged periods of time, 
were anticipated to be much lower than the LLQ of 
the previously developed methodology. Furthermore, 
an assay for I in urine was developed to determine 
the magnitude of the renal clearance of I in studies 
after i.v. administration. 
2. Experimental 
2.1. Chemicals and reagents 
Compound I was obtained from Smith Kline 
Beecham Pharmaceuticals (King of Prussia, PA, 
USA). Methanol (HPLC-grade) was obtained from 
Rathburn and supplied by Brunschwig (Amsterdam, 
Netherlands). Triethylamine, potassium dihydrogen- 
phosphate, sodium hydroxide and acetic acid (all 
analytical grade) were obtained from Baker (Deven- 
ter, Netherlands). Orthophosphoric acid (analytical 
grade) was obtained from Merck (Amsterdam, 
Netherlands). Phosphate-buffered saline (PBS) was 
obtained from Oxoid and supplied by Boom (Mep- 
pel, Netherlands). PBS consisted of sodium chloride 
(8.0 g/l), potassium chloride (0.2 g/l), disodium 
hydrogenphosphate (1.15 g/l) and potassium di- 
hydrogenphosphate (0.2 g/l) and was supplied in 
tablet form. One tablet was dissolved in 100 ml of 
purified water. The water was purified with a Milli- 
Q-UF system (Millipore, Ettenleur, Netherlands). 
A stock solution containing 1.0 mg/ml of I was 
made by dissolving 50.0 mg of I in 50.00 ml of 
purified water. To 5.00 ml of the stock solution in 
water, 45.00 ml of a 0.10% acetic acid solution were 
added. This solution contained 0.10 mg/ml of I. To 
another 5.00 ml of the stock solution, 45.00 ml of a 
0.10 M sodium hydroxide solution were added. This 
solution contained 0.10 mg/ml of II. 
2.2. Chromatographic system 
The HPLC system consisted of a constaMetric 
4100 pump (Thermo Separations), a Rheodyne 7125 
injection port and a fluoriMonitor 4100 fluorescence 
detector (LDC Analytical). The data were analyzed 
by the Chrom-Card data analysis system (Fisons). 
These apparatuses were obtained from Interscience 
(Breda, Netherlands). The separation was achieved 
on a Shandon Hypersil BDS C~8 column (100 mm X 
3 mm I.D., 3 /zm particle size), delivered by LC 
Service (Emmen, Netherlands). A Model SpH 99 
column oven, delivered by Spark Holland (Meppel, 
Netherlands), was set at 35°C for the plasma assay 
and at 60°C for the urine assay. The excitation 
wavelength was set at 381 nm and the emission 
wavelength was set at 525 nm. 
For the assay in plasma, the mobile phase con- 
sisted of 10 mM potassium dihydrogenphosphate 
(filtered through a 0.45-/zm HA Millipore filter, 
Millipore) containing 25% methanol and 0.2% tri- 
ethylamine. The pH was adjusted to pH 6.0 by the 
addition of orthophosphoric a id. The mobile phase 
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was degassed using ultrasound and helium. The 
flow-rate was set at 0.70 ml/min. 
For the assay in urine, the mobile phase consisted 
of 20% methanol instead of 25%. The flow-rate was 
set at 1.00 ml/min. 
2.3. Sample preparation and calibration curves in 
plasma 
Immediately after preparing the standards, 250/xl 
of plasma were added to 750/zl of cold methanol of 
-20°C, according to the method of Beijnen et al. 
[11]. After mixing on a vortex-mixer for 10 s, the 
samples were centrifuged for 5 min at 4000 g, at 
4°C, and stored at -80°C. Plasma samples from 
patients were stored, after mixing, at -80°C and 
centrifuged on the day of analysis. Prior to analysis, 
250/~1 of the supernatant were added to 750 ~1 of 
PBS and mixed on a vortex-mixer for 10 s. A 200-/zl 
volume was injected into the HPLC. 
For the validation of the assay in plasma, a nine- 
point calibration curve was processed, in duplicate 
(Table 1), and analyzed on three occasions. For the 
determination of the LLQ, six plasma samples from 
six independent individuals were taken and spiked 
with 0.10 ng/ml of both compounds. Also, four 
pools of quality control (QC) samples were prepared. 
Plasma pools were spiked with 0.50, 2.00, 4.00 and 
20.00 ng/ml of both compounds. The QC sample 
containing 20.00 ng/ml was used for subsequent 
dilutions. On each run, the QC samples were ana- 
lyzed five times. 
The recovery of I and II was determined at 
concentrations of 2.00 and 4.00 ng/ml in plasma. 
The peak heights of five analyzed plasma samples 
were compared with the peak heights of two spiked 
concentrations, of 2.00 and 4.00 ng/ml in PBS. 
Calibration curves were made by linear regression 
analysis of peak heights versus concentration. For 
the concentration accepted as the LLQ, the per- 
centage deviation (% DEV) of at least 80% of the 
samples assayed should be -< 20%. The average 
within- and between-run precision (%C.V.) for each 
concentration, excluding the LLQ, should be -< 15% 
and should be -< 20% for the LLQ. The average 
accuracy (%) for each concentration, including the 
LLQ, should be within 85-115%. 
2.4. Urine sample preparation and calibration 
curve 
In urine, the total concentration f I was measured 
after conversion of II into I. To 250/xl of urine, 250 
/xl of a 100-fold dilution of pure orthophosphoric 
acid were added. After mixing on a vortex-mixer for 
10 s, the mixture was incubated for at least 10 min at 
room temperature. Prior to injection, 50 /zl of this 
mixture were added to 950/zl of PBS and mixed on 
a vortex-mixer for 10 s. A 20-/xl volume was 
injected into the HPLC. 
For the validation of the assay in urine, a seven- 
point calibration curve was prepared (Table 2). The 
calibration curves were made in duplicate and ana- 
lyzed on three occasions. For the determination of 
the LLQ, ten urine samples from ten independent 
individuals were taken and spiked with 10 ng/ml of 
I. Pools of QC samples were spiked with 25, 100, 
200 and 1000 ng/ml of I. The QC sample of 1000 
ng/ml was used for all subsequent dilutions. In each 
run, the QC samples were processed five times. 
The recovery of I was determined at concen- 
Table 1 
Preparation fthe "calibration curves in plasma 
Final concentration f I and II (ng/ml) 
5.00 3.00 2.00 1.00 0.50 0.30 0.20 0.15 0.10 
Plasma dded (/zl) 500 700 800 1800 500 700 800 850 900 
10.0 ng/ml I and II added (/zl) 500 300 200 200 
1.00 ng/ml I and II added (/zl) 500 300 200 150 100 
Solutions containing 0.10 mg/ml of I and 0.10 mg/ml of II were separately diluted 100-fold with PBS and again 10-fold with plasma. 
A-200 /zl volume of both solutions was added to 1600 /zl of plasma. This solution contained 10.0 ng/ml of I and II. 
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Table 2 
Preparation of the calibration curve in urine 
Final concentration of I (ng/ml) 
250 200 150 100 50 25 10 
Urine added (/zl) 750 800 850 900 500 500 900 
1000 ng/ml of I added (/zl) 250 200 150 100 
100 ng/ml of I added (/zl) 500 100 
50 ng/ml of I 500 
A solution containing 0.10 mg/ml of I was diluted 100-fold in urine. This results in a 1000 ng/ml solution of I. 
trations of 100 and 200 ng/ml in urine. The pro- 
cedure is the same as the procedure described for 
plasma. 
Calibration curves were constructed by linear 
regression analysis of peak heights versus concen- 
tration. The same acceptance criteria were applied as 
those described for plasma samples. 
2.5. Stability of I and H in plasma and urine 
The stability of I and II was tested in plasma 
extracts and in urine at different emperatures. 
In plasma, the stability of both compounds was 
tested by incubating plasma with extracts containing 
either I alone or II alone, for 24 h at room tempera- 
ture (22°C), 4°C and at -20°C. The stability at 
-80°C, the storage temperature for patients' sam- 
ples, was tested with methanolic plasma mixtures 
containing both compounds. 
In urine, the stability of I was tested by incubation 
of urine with I for 24 h at 4°C, 22°C and at 37°C and 
also in urine that was diluted one-fold with ortho- 
phosphoric acid (l:100, v/v), at 22°C. Also, the 
stability of I in urine, at -80°C, was tested. 
2.6. Human experiments 
In an oral phase I study, the starting dose was 0.15 
mg/m 2. On days 1 and 8, blood samples were 
collected for up to 12 h. One of the first patients was 
treated with a dose of 0.4 mg. Immediately after 
sampling, the blood was centrifuged for 5 min at 
3500 g and the plasma was treated as outlined. 
In another study, where I is administered intraven- 
ously at a low daily dose of 0.5 mg/m 2, urine 
samples were collected also. 
3. Results 
3.1. Assay in plasma 
The calibration curves of I and II in plasma were 
linear in the range of 0.10 to 5.00 ng/ml, with 
correlation coefficients of at least 0.9986. The re- 
tention time of II is 2.5 min and that of I is 6.5 min 
(Fig. 2). No significant interfering peaks were found 
in six independent blank plasma samples. The LLQ 
for both compounds in plasma was 0.10 ng/ml. The 
mean recovery of I in plasma was 99.3% and of II 
was 100.6%. The within-run precision of the LLQ 
samples of I was 4.4% and of II was 9.7%. The 
accuracies were 93.2% and 106.6%, respectively. 
The between-run precision of the LLQ was calcu- 
lated using the lowest concentration of the individual 
calibration curves used for the validation of the 
assay. The between-run precisions were 7.1 and 
5.5%, respectively. The average values for the 
accuracy, within-run precision and the between-run 
precision of the QC samples are given in Table 3. 
3.2. Assay in urine 
The calibration curves of I in urine were linear in 
the range of 10 to 250 ng/ml with correlation 
coefficients of at least 0.9984. Also for the assay in 
urine no significant interfering peaks for I were 
found. The LLQ was established at 10 ng/ml 
(concentrations in the clinical studies were not 
expected to be lower than 10 ng/ml). The mean 
recovery of I in urine was 101.9%. The within-run 
precision of the LLQ samples was 7.2%, the be- 
tween-run precision was 5.4% and the accuracy of 
the LLQ was 97.6%. The average values of the 
accuracy, the within-run precision and the between- 
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Fig. 2, Chromatograms of a blank blood sample (A) and of a blood sample containing 0.78 ng/ml of I and 0.24 ng/ml of II (B). 
run precision of the QC samples are given in Table 
4. 
3.3. Stability of I and H in plasma and of I in 
urine 
The reversible hydrolysis of I in plasma extracts is 
dependent on the temperature. Compounds I and II 
were found to be unstable at 4°C and at 22°C. There 
was no hydrolysis at -20°C (Fig. 3). Compounds I 
and II were stable in methanolic plasma mixtures for 
at least 4 months at -80°C. 
The stability of I in urine was also dependent on 
the temperature. At 37°C, I was found to be unstable, 
at 22°C it was moderately stable and at 4°C, I was 
stable for 24 h. Compound I was stable at 22°C after 
dilution with orthophosphoric acid (Fig. 4). At 
-80°C, I was stable for more than 3 months. 
3.4. Human experiment 
The plasma concentration-time curves of I and II 
from the patient reated with 0.4 mg of I are given in 
Fig. 5. 
The concentration of I in the urine samples of 
Table 3 
The average accuracy, within-run precision and between-run precision of I and II in the QC samples in plasma 
QC sample Average accuracy (%) Precision (%) 
(ng/ml) 
I II Within-run (mean) Between-run 
I II I II 
0,50 102.7 101.3 2.8 1.5 6.9 6.3 
2.00 108.4 106.5 3.8 1.3 8.6 5.2 
4.00 102.8 102.6 3.1 1.0 5.0 5.5 
20.00 103.3 102.3 3.9 3.7 3.0 3.5 
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Table 4 
The average accuracy, within-run precision and between-run precision of I in the QC samples in urine 
QC sample Average accuracy (%) Precision (%) 
(ng/ml) 
Within-run (mean) Between-run 
25 99.7 4.4 3.3 
1~ 97.5 4.1 0.6 
2~ 97.8 5.3 1.8 
1000 98.9 3.2 2.0 
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Fig. 3. Stability of I and II in plasma extracts, at different 
temperatures for 24 h. ~i' 
patients who were treated using the intravenous 
protocol were all > l0 ng/ml (data not shown). 
4. Discussion 
The described methodology for the assay in 
plasma with an LLQ of 0.10 ng/ml for I and II is 
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Fig. 4. Stability of I in urine at different emperatures and when 
diluted one-fold with orthophosphoric a id. 
appropriate for the measurement of plasma samples 
in ongoing clinical studies, where low daily doses 
are administered. For the assay in urine, the LLQ of 
l0 ng/ml was also satisfactory. Both compounds 
were unstable in plasma extracts at 4°C and at 22°C. 
In urine, I was found to be unstable at 37°C and 
moderately stable at 22°C. Methanolic plasma mix- 
tures and urine stored at -80°C were found to be 
stable for at least 4 and 3 months, respectively. 
In urine, only I was measured after acidification, 
to ensure total conversion of II into I. 
5. Conclusion 
A sensitive, selective, accurate and reproducible 
isocratic reversed-phase HPLC method has been 
developed for the simultaneous analyses of I and II 
in plasma and for the analysis of I in urine. Plasma 
sample pretreatment was carried out immediately 
after sample collection by deproteinizing the sample 
with cold methanol, as previously described [11]. 
Prior to injection, the sample was diluted with PBS. 
The urine samples were analyzed after acidification 
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Fig. 5. Plasma concentration-time curve of I and [I after oral 
administration of 0.4 mg on days 1 and 8. 
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with orthophosphoric acid and dilution with PBS. 
The methodology described for the measurement of 
plasma concentrations of both compounds and of 
urine concentrations of I can be used to determine 
the pharmacokinetics in clinical studies when I is 
administered at low doses. 
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